<bill session="117" type="h" number="3354" updated="2023-01-11T13:49:41Z">
  <state datetime="2021-05-19">REFERRED</state>
  <status>
    <introduced datetime="2021-05-19"/>
  </status>
  <introduced datetime="2021-05-19"/>
  <titles>
    <title type="display">CHANGE Act of 2021</title>
    <title type="official" as="introduced">To provide better care and outcomes for Americans living with Alzheimer's disease and related dementias and their caregivers while accelerating progress toward prevention strategies, disease modifying treatments, and, ultimately, a cure.</title>
    <title type="short" as="introduced">CHANGE Act of 2021</title>
    <title type="short" as="introduced">Concentrating on High-value Alzheimer&#226;&#8364;&#8482;s Needs to Get to an End Act of 2021</title>
  </titles>
  <sponsor bioguide_id="S001156"/>
  <cosponsors>
    <cosponsor bioguide_id="A000378" joined="2021-10-19"/>
    <cosponsor bioguide_id="B001298" joined="2022-05-17"/>
    <cosponsor bioguide_id="B001300" joined="2021-05-19"/>
    <cosponsor bioguide_id="B001281" joined="2022-08-19"/>
    <cosponsor bioguide_id="B001304" joined="2022-05-12"/>
    <cosponsor bioguide_id="C001080" joined="2021-08-24"/>
    <cosponsor bioguide_id="C001053" joined="2021-05-19"/>
    <cosponsor bioguide_id="D000631" joined="2022-05-17"/>
    <cosponsor bioguide_id="D000191" joined="2021-05-19"/>
    <cosponsor bioguide_id="D000627" joined="2021-05-19"/>
    <cosponsor bioguide_id="D000482" joined="2021-05-19"/>
    <cosponsor bioguide_id="F000466" joined="2021-05-19"/>
    <cosponsor bioguide_id="G000551" joined="2021-05-19"/>
    <cosponsor bioguide_id="G000576" joined="2021-05-19"/>
    <cosponsor bioguide_id="K000375" joined="2021-05-19"/>
    <cosponsor bioguide_id="K000389" joined="2022-05-06"/>
    <cosponsor bioguide_id="K000378" joined="2021-05-19"/>
    <cosponsor bioguide_id="K000382" joined="2021-05-19"/>
    <cosponsor bioguide_id="L000585" joined="2021-05-19"/>
    <cosponsor bioguide_id="L000273" joined="2021-07-09"/>
    <cosponsor bioguide_id="L000579" joined="2021-05-19"/>
    <cosponsor bioguide_id="M001163" joined="2021-05-19"/>
    <cosponsor bioguide_id="M000312" joined="2022-05-11"/>
    <cosponsor bioguide_id="N000179" joined="2021-06-14"/>
    <cosponsor bioguide_id="N000192" joined="2021-05-19"/>
    <cosponsor bioguide_id="N000147" joined="2021-05-19"/>
    <cosponsor bioguide_id="P000604" joined="2022-05-11"/>
    <cosponsor bioguide_id="P000607" joined="2022-06-03"/>
    <cosponsor bioguide_id="P000599" joined="2021-05-19"/>
    <cosponsor bioguide_id="R000606" joined="2021-06-22"/>
    <cosponsor bioguide_id="R000486" joined="2022-06-07"/>
    <cosponsor bioguide_id="S000168" joined="2022-07-11"/>
    <cosponsor bioguide_id="S001157" joined="2022-08-19"/>
    <cosponsor bioguide_id="S001207" joined="2021-05-19"/>
    <cosponsor bioguide_id="S001211" joined="2022-09-21"/>
    <cosponsor bioguide_id="S001215" joined="2021-05-19"/>
    <cosponsor bioguide_id="S001201" joined="2021-05-19"/>
    <cosponsor bioguide_id="T000472" joined="2021-05-20"/>
    <cosponsor bioguide_id="T000468" joined="2022-05-17"/>
    <cosponsor bioguide_id="T000481" joined="2022-08-12"/>
    <cosponsor bioguide_id="U000031" joined="2021-05-19"/>
    <cosponsor bioguide_id="V000132" joined="2021-06-30"/>
    <cosponsor bioguide_id="W000187" joined="2021-05-19"/>
    <cosponsor bioguide_id="W000800" joined="2021-05-19"/>
    <cosponsor bioguide_id="W000826" joined="2021-10-08"/>
  </cosponsors>
  <actions>
    <action datetime="2021-05-19">
      <text>Introduced in House</text>
    </action>
    <action datetime="2021-05-19" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2021-05-19">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2021-05-20">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="1692" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Aging"/>
    <term name="Congressional oversight"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care quality"/>
    <term name="Health information and medical records"/>
    <term name="Health promotion and preventive care"/>
    <term name="Medical research"/>
    <term name="Medical tests and diagnostic methods"/>
    <term name="Medicare"/>
    <term name="Neurological disorders"/>
    <term name="Public-private cooperation"/>
    <term name="Research administration and funding"/>
  </subjects>
  <amendments/>
  <summary date="2021-10-19T14:30:54Z" status="Introduced in House">Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2021 or the CHANGE Act of 2021 This bill modifies the requirements under Medicare for diagnosing and treating Alzheimer's disease and other cognitive impairments in older adults. Specifically, the bill expands the cognitive impairment detection benefit during annual wellness visits to require the use of validated detection tools and documentation of the results in the patient's medical record. Further, when a cognitive impairment is detected, the patient must be referred to an appropriate diagnostic service provider and other specified supports. Additionally, the Centers for Medicare &amp; Medicaid Services must implement Medicare policies that increase the identification and response to patients' Alzheimer's disease risk factors and incentivize providers to utilize high-quality cognitive impairment diagnosis practices. The Government Accountability Office also must conduct a study of policies that may accelerate progress in Alzheimer's disease research and enhance the quality of care for individuals diagnosed with Alzheimer's disease.</summary>
</bill>
